お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
919481

血液検査 - 医療機器パイプライン評価:2019年

Hemostasis Tests - Medical Devices Pipeline Assessment, 2020

出版日: | 発行: GlobalData | ページ情報: 英文 206 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.77円
血液検査 - 医療機器パイプライン評価:2019年
出版日: 2020年12月01日
発行: GlobalData
ページ情報: 英文 206 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の血液検査市場について調査し、主要なパイプライン製品の詳細 (製品説明、ライセンシング、コラボレーション詳細、その他の開発活動) 、主要企業とそのパイプラインプロジェクト、様々な開発段階に基づいたパイプライン製品のレビュー、主な臨床試験データ、セグメント/産業における近年の開発動向などを提供しています。

第1章 目次

第2章 イントロダクション

第3章 開発中の製品

  • パイプライン製品:開発段階別
  • パイプライン製品:セグメント別
  • パイプライン製品:テリトリー別
  • パイプライン製品:規制手続き別
  • パイプライン製品:予測される承認日別

第4章 血液検査:開発中のパイプライン製品、企業別

  • 血液検査企業 - パイプライン製品:開発段階別
  • 血液検査 - パイプライン製品:開発段階別

第5章 血液検査企業・製品の概要

第6章 血液検査:近年の発展

第7章 付録

図表

List of Tables

List of Tables

  • Table 1: Hemostasis Tests - Pipeline Products by Stage of Development
  • Table 2: Hemostasis Tests - Pipeline Products by Segment
  • Table 3: Hemostasis Tests - Pipeline Products by Territory
  • Table 4: Hemostasis Tests - Pipeline Products by Regulatory Path
  • Table 5: Hemostasis Tests - Pipeline Products by Estimated Approval Date
  • Table 6: Hemostasis Tests Companies - Pipeline Products by Stage of Development
  • Table 7: Hemostasis Tests - Pipeline Products by Stage of Development
  • Table 8: Alere Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: Afinion PT Test - Capillary Blood - Product Status
  • Table 10: Afinion PT Test - Capillary Blood - Product Description
  • Table 11: Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 12: Coagulyzer 1 - Product Status
  • Table 13: Coagulyzer 1 - Product Description
  • Table 14: Coagulyzer 100 - Product Status
  • Table 15: Coagulyzer 100 - Product Description
  • Table 16: Coagulyzer 2 - Product Status
  • Table 17: Coagulyzer 2 - Product Description
  • Table 18: Coagulyzer 4 - Product Status
  • Table 19: Coagulyzer 4 - Product Description
  • Table 20: Atantares Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 21: Platelet Function Assay - Product Status
  • Table 22: Platelet Function Assay - Product Description
  • Table 23: Atomo Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 24: AtomoRapid - Coagulation Monitoring - Product Status
  • Table 25: AtomoRapid - Coagulation Monitoring - Product Description
  • Table 26: BioMedica USA LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • Table 27: Portable Diagnostic System - Hemostasis - Product Status
  • Table 28: Portable Diagnostic System - Hemostasis - Product Description
  • Table 29: Braun Biosystems, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • Table 30: Bio6 - Product Status
  • Table 31: Bio6 - Product Description
  • Table 32: Carclo Diagnostic Solutions Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 33: Micropoc-CAT - Haemostasis Assay - Product Status
  • Table 34: Micropoc-CAT - Haemostasis Assay - Product Description
  • Table 35: Diagnostica Stago Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 36: Calibrated Automated Thrombogram - Thrombin Assay - Product Status
  • Table 37: Calibrated Automated Thrombogram - Thrombin Assay - Product Description
  • Table 38: STA Compact Max - NeoPTimal ISI - Product Status
  • Table 39: STA Compact Max - NeoPTimal ISI - Product Description
  • Table 40: STA Compact Max - Ristocetin Cofactor Assay - Product Status
  • Table 41: STA Compact Max - Ristocetin Cofactor Assay - Product Description
  • Table 42: STA Compact Max - Rivaroxaban Calibrators And Controls For Anti-Xa - Product Status
  • Table 43: STA Compact Max - Rivaroxaban Calibrators And Controls For Anti-Xa - Product Description
  • Table 44: STA-R Evolution Expert - Automated Ecarin Chromogenic Assay - Product Status
  • Table 45: STA-R Evolution Expert - Automated Ecarin Chromogenic Assay - Product Description
  • Table 46: STA-R Evolution Plus - Automated Ecarin Chromogenic Assay - Product Status
  • Table 47: STA-R Evolution Plus - Automated Ecarin Chromogenic Assay - Product Description
  • Table 48: STA-R Evolution Plus - Rivaroxaban and Apixaban Calibrators And Controls For Anti-Xa - Product Status
  • Table 49: STA-R Evolution Plus - Rivaroxaban and Apixaban Calibrators And Controls For Anti-Xa - Product Description
  • Table 50: STA-R Max - NeoPTimal ISI - Product Status

List of Figures

List of Figures

  • Figure 1: Hemostasis Tests - Pipeline Products by Stage of Development
  • Figure 2: Hemostasis Tests - Pipeline Products by Segment
  • Figure 3: Hemostasis Tests - Pipeline Products by Territory
  • Figure 4: Hemostasis Tests - Pipeline Products by Regulatory Path
  • Figure 5: Hemostasis Tests - Pipeline Products by Estimated Approval Date
目次
Product Code: GDME1088EPD

GlobalData's Medical Devices sector report, "Hemostasis Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Hemostasis Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Hemostasis screening tests help identify patients with hemostatic defects. It includes the sub-segments Prothrombin time tests, Prothrombin time (PT) POC test, Prothrombin time laboratory tests, Activated partial thromboplastin time (aPTT or PTT) tests, Activated partial thromboplastin time (aPTT) POC tests, Activated partial thromboplastin time (aPTT or PTT) laboratory tests, D-dimer tests, D-dimer POC test and D-dimer laboratory tests.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Hemostasis Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Hemostasis Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Hemostasis Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

  • 1.2 List of Figures
  • 2.1 Hemostasis Tests Overview

3 Products under Development

  • 3.1 Hemostasis Tests - Pipeline Products by Stage of Development
  • 3.2 Hemostasis Tests - Pipeline Products by Segment
  • 3.3 Hemostasis Tests - Pipeline Products by Territory
  • 3.4 Hemostasis Tests - Pipeline Products by Regulatory Path
  • 3.5 Hemostasis Tests - Pipeline Products by Estimated Approval Date

4 Hemostasis Tests - Pipeline Products under Development by Companies

  • 4.1 Hemostasis Tests Companies - Pipeline Products by Stage of Development
  • 4.2 Hemostasis Tests - Pipeline Products by Stage of Development

5 Hemostasis Tests Companies and Product Overview

  • 5.1 Alere Inc Company Overview
    • 5.1.1 Alere Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2 Analyticon Biotechnologies AG Company Overview
    • 5.2.1 Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3 Atantares Corp Company Overview
    • 5.3.1 Atantares Corp Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4 Atomo Diagnostics Ltd Company Overview
    • 5.4.1 Atomo Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5 BioMedica USA LLC (Inactive) Company Overview
    • 5.5.1 BioMedica USA LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • 5.6 Braun Biosystems, Inc. (Inactive) Company Overview
    • 5.6.1 Braun Biosystems, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • 5.7 Carclo Diagnostic Solutions Ltd Company Overview
    • 5.7.1 Carclo Diagnostic Solutions Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.8 Diagnostica Stago Inc Company Overview
    • 5.8.1 Diagnostica Stago Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.9 Edan Instruments Inc Company Overview
    • 5.9.1 Edan Instruments Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.10 EKF Diagnostics Holdings Plc Company Overview
    • 5.10.1 EKF Diagnostics Holdings Plc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.11 Emosis SAS Company Overview
    • 5.11.1 Emosis SAS Pipeline Products & Ongoing Clinical Trials Overview
  • 5.12 Fraunhofer Institute for Cell Therapy and Immunology Company Overview
    • 5.12.1 Fraunhofer Institute for Cell Therapy and Immunology Pipeline Products & Ongoing Clinical Trials Overview
  • 5.13 Grifols SA Company Overview
    • 5.13.1 Grifols SA Pipeline Products & Ongoing Clinical Trials Overview
  • 5.14 Hansjorg Wyss Institute for Biologically Inspired Engineering Company Overview
    • 5.14.1 Hansjorg Wyss Institute for Biologically Inspired Engineering Pipeline Products & Ongoing Clinical Trials Overview
  • 5.15 Helena Laboratories Corp Company Overview
    • 5.15.1 Helena Laboratories Corp Pipeline Products & Ongoing Clinical Trials Overview
  • 5.16 HemoSonics LLC Company Overview
    • 5.16.1 HemoSonics LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.17 Instrumentation Laboratory Co Company Overview
    • 5.17.1 Instrumentation Laboratory Co Pipeline Products & Ongoing Clinical Trials Overview
  • 5.18 Levisonics Inc Company Overview
    • 5.18.1 Levisonics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.19 Massachusetts General Hospital Company Overview
    • 5.19.1 Massachusetts General Hospital Pipeline Products & Ongoing Clinical Trials Overview
  • 5.20 Novametics Inc (Inactive) Company Overview
    • 5.20.1 Novametics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • 5.21 Ortho-Clinical Diagnostics Inc Company Overview
    • 5.21.1 Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.22 Pakwa Technologies Company Overview
    • 5.22.1 Pakwa Technologies Pipeline Products & Ongoing Clinical Trials Overview
  • 5.23 PortaScience Inc Company Overview
    • 5.23.1 PortaScience Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.24 Radiometer Medical ApS Company Overview
    • 5.24.1 Radiometer Medical ApS Pipeline Products & Ongoing Clinical Trials Overview
  • 5.25 Rappaport Family Institute for Research in the Medical Science Company Overview
    • 5.25.1 Rappaport Family Institute for Research in the Medical Science Pipeline Products & Ongoing Clinical Trials Overview
  • 5.26 rHealth Company Overview
    • 5.26.1 rHealth Pipeline Products & Ongoing Clinical Trials Overview
  • 5.27 Roche Diagnostics International Ltd Company Overview
    • 5.27.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.28 Sekisui Diagnostics LLC Company Overview
    • 5.28.1 Sekisui Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.29 Siemens Healthcare Diagnostics GmbH Company Overview
    • 5.29.1 Siemens Healthcare Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • 5.30 Siemens Healthcare Diagnostics Inc Company Overview
    • 5.30.1 Siemens Healthcare Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.31 Siemens Healthineers AG Company Overview
    • 5.31.1 Siemens Healthineers AG Pipeline Products & Ongoing Clinical Trials Overview
  • 5.32 SonoMedix, Inc. Company Overview
    • 5.32.1 SonoMedix, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.33 SQI Diagnostics Inc Company Overview
    • 5.33.1 SQI Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.34 Stichting Lygature Company Overview
    • 5.34.1 Stichting Lygature Pipeline Products & Ongoing Clinical Trials Overview
  • 5.35 Sysmex Corp Company Overview
    • 5.35.1 Sysmex Corp Pipeline Products & Ongoing Clinical Trials Overview
  • 5.36 Tarabios Company Overview
    • 5.36.1 Tarabios Pipeline Products & Ongoing Clinical Trials Overview
  • 5.37 The Binding Site Group Ltd Company Overview
    • 5.37.1 The Binding Site Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.38 ThromboTherapeutics Inc Company Overview
    • 5.38.1 ThromboTherapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.39 Transfusion & Transplantation Technologies (Inactive) Company Overview
    • 5.39.1 Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • 5.40 Universal Biosensors Inc Company Overview
    • 5.40.1 Universal Biosensors Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.41 University of Colorado Company Overview
    • 5.41.1 University of Colorado Pipeline Products & Ongoing Clinical Trials Overview
  • 5.42 University of Michigan Company Overview
    • 5.42.1 University of Michigan Pipeline Products & Ongoing Clinical Trials Overview
  • 5.43 University of Texas Health Science Center at Houston Company Overview
    • 5.43.1 University of Texas Health Science Center at Houston Pipeline Products & Ongoing Clinical Trials Overview
  • 5.44 University of Vermont Company Overview
    • 5.44.1 University of Vermont Pipeline Products & Ongoing Clinical Trials Overview

6 Hemostasis Tests- Recent Developments

  • 6.1 Nov 12, 2020: Earnings release Q4 FY 2020 : Siemens
  • 6.2 Aug 06, 2020: Earnings release and financial results Q3 FY 2020: Strong team performance in challenging times
  • 6.3 Aug 06, 2020: Siemens profit falls on COVID-19 issues, taxes
  • 6.4 Jul 23, 2020: Abcam: provides full year trading update 2020
  • 6.5 Jul 13, 2020: Judith Wiese appointed managing board member and labor director of Siemens AG
  • 6.6 Jul 13, 2020: Thermo Fisher Scientific and first genetics JCS partner to develop next-generation sequencing-based diagnostics in Russia
  • 6.7 Jul 08, 2020: Michael Peter to be Siemens Mobility's sole CEO
  • 6.8 Jun 09, 2020: Siemens and Exyte join forces to deliver integrated solutions for fast-track construction of smart biotech facilities
  • 6.9 Apr 14, 2020: Siemens Managing Board sets up COVID-19 aid fund
  • 6.10 Mar 02, 2020: Russia's sanctions-hit Power Machines to sell its stake in JV with Siemens
  • 6.11 Feb 27, 2020: Grifols reaches revenue of EUR 5,100 million, a 13.6% increase, and raises its profits to EUR 625 million
  • 6.12 Feb 27, 2020: SQI Diagnostics reports first quarter 2020 results
  • 6.13 Feb 26, 2020: BioPorto announces preliminary financial result for 2019, guidance for 2020 and postpones publication of audited annual report for 2019 to March 11, 2020
  • 6.14 Feb 26, 2020: Thermo Fisher Scientific President and Chief Executive Officer Marc N. Casper elected Chairman of the Board of Directors
  • 6.15 Feb 24, 2020: 2020 Catalyst award winner Medtronic hires Chief Inclusion and Diversity Officer
  • 6.16 Feb 24, 2020: 2020 Catalyst Award Winner Medtronic hires Chief Inclusion and Diversity Officer
  • 6.17 Feb 18, 2020: Medtronic reports third quarter financial results 2020
  • 6.18 Feb 18, 2020: Hologic Expands Costa Rican operations with new financial shared services center
  • 6.19 Feb 05, 2020: Hologic launches new scalable options for panther system in the United States and Europe
  • 6.20 Feb 03, 2020: Siemens Healthineers starts new fiscal year with strong growth - outlook confirmed
  • 6.21 Jan 30, 2020: Thermo Fisher Scientific reports fourth quarter and full year 2019 results
  • 6.22 Jan 30, 2020: Peter Korte to head Siemens Strategy
  • 6.23 Jan 15, 2020: Accellix announces the appointment of Nir Nimrodi as chairman and chief executive officer
  • 6.24 Jan 14, 2020: ABCAM: Appointment of Chief Financial Officer
  • 6.25 Jan 13, 2020: T2 Biosystems promotes Tony Pare to Chief Commercial Officer
  • 6.26 Jan 12, 2020: Hologic announces preliminary financial results for first quarter of fiscal 2020
  • 6.27 Jan 12, 2020: Baxter announces preliminary net sales for the fourth-quarter and full-year 2019 and announces preliminary full-year 2020 guidance
  • 6.28 Jan 10, 2020: Abcam : Half year trading update
  • 6.29 Jan 09, 2020: rHEALTH Technology granted US patent for small volume blood handling in point-of-care devices
  • 6.30 Jan 09, 2020: T2 Biosystems announces preliminary fourth quarter 2019 financial results
  • 6.31 Jan 09, 2020: T2 Biosystems appoints industry veteran John Sperzel as chief executive officer
  • 6.32 Jan 09, 2020: Pomerantz law firm investigates claims on behalf of investors of Baxter
  • 6.33 Jan 02, 2020: Agilent expands cross-vendor CDS instrument control
  • 6.34 Dec 31, 2019: Redbud Labs expands team in response to increased demand
  • 6.35 Dec 11, 2019: SQI Diagnostics Reports Fourth Quarter and Fiscal 2019 Results and Management Changes
  • 6.36 Dec 10, 2019: Siemens Healthineers gives details on second phase of Strategy 2025 and on the further development of its businesses
  • 6.37 Dec 04, 2019: Lumeon and Medtronic partner to deliver new models of care in Europe
  • 6.38 Dec 02, 2019: Rosen, a highly ranked firm, announces filing of securities class action lawsuit against Baxter International

7 Appendix

  • 7.1 Methodology
  • 7.2 About GlobalData
  • 7.3 Contact Us
  • 7.4 Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.